Background: M. tuberculosis grows slowly and requires several weeks to detect in clinical specimens using standard culture techniques. Messenger RNA is more rapidly destroyed in cells than rRNA or genomic DNA, assays that target mycobacterial mRNA better reflect mycobacterial viability. Therefore we evaluated performance of mRNA for monitoring response to antituberculosis therapy using Real-Time PCR. Methods: Sputum specimens from 29 tuberculosis patients confirmed by positive culture were included in this study. Sputum specimens were collected before therapy, at 1st week, 4th week, 8th week and 16th week after initiating antituberculosis therapy to evaluate acid-fast bacilli (AFB), culture and mRNA level. Results: All 29 specimens were positive for culture and mRNA before initiating tuberculosis chemotherapy. Within 29 samples confirmed by positive culture, only 22 (75.9%) patients were positive by AFB. After 8 and 16 weeks of therapy, 27 (93.1%) and 28 (96.5%) were negative by culture, 26 (89.6%) and 28 (96.5%) were negative results for mRNA, and 15 (51.7%) and 29 (100%) were negative results for AFB. Conclusion: Rapidly decline of mRNA level correlated with rapid culture clearance after anti-tuberculosis therapy.
| Published in | American Journal of Clinical and Experimental Medicine (Volume 3, Issue 1) |
| DOI | 10.11648/j.ajcem.20150301.11 |
| Page(s) | 1-5 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
M. tuberculosis, mRNA, Real-Time PCR
| [1] | WHO: Global Tuberculosis Report 2013. WHO Press 2013: http://www.who.int/tb/publications/global_report/en/. |
| [2] | Therese, L. K., Gayathri, R., Dhanurekha, L., Sridhar, R., Meenakshi, N., Madhavan, H. N., et al.: Detection of Mycobacterium tuberculosis directly from sputum specimens & phenotypic drug resistance pattern of M. tuberculosis isolates from suspected tuberculosis patients in Chennai. Indian J Med Res 2012, (135):778-782. |
| [3] | WHO: Global tuberculosis control - surveillance, planning, financing. 2008. |
| [4] | Hatta, M., Sultan, A. R., Dwiyanti, R., Sabir, M., Febrianty, A., Adhyka, A., et al: The Reproducibility of the multiplex RAPD-PCR assay in genotyping of Mycobacterium tuberculosis isolates from Sulawesi, Indonesia. American Journal of Clinical and Experimental Medicine, 2014, 2(2):14-21. |
| [5] | Caminero JA: Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010, 14(4):382-390. |
| [6] | Golub JE, Mohan CI, Comstock GW, and Chaisson RE: Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005, 9(11):1183-1203. |
| [7] | Barkan, D., Liu, Z., Sacchettini, J. C., & Glickman, M. S: Mycolic Acid Cyclopropanation is Essential for Viability, Drug Resistance, and Cell Wall Integrity of Mycobacterium tuberculosis. Chemistry & Biology 2009, 16:499–509. |
| [8] | WHO: Countdown to 2015 Global Tuberculosis Report 2013 Supplement. Geneva: WHO Press 2013. |
| [9] | Mdivani, N., Li, H., Akhalaia, M., Gegia, M., Goginashvili, L., Kernodle, D. S., et al.: Monitoring Therapeutic Efficacy by Real-Time Mycobacterium tuberculosis mRNA Detection in Sputum. ClinChem 2010, 55(9):1694–1700. |
| [10] | Noodhoek GT, Kolk AHJ, Bjune D, and Catty JW: Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. Fine PEM 1994, 32:277-284. |
| [11] | Hatta M, Sultan AR, Tandirogang N, Masjudi, Yadi: Detection and identification of mycobacteria in sputum from suspected tuberculosis patients. BMC Res Notes 2010, 3:72. |
| [12] | Kox LFF, Leeuwen van J, Kuijper S, Jansen HM, Kolk AHJ: PCR assay bases on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. J Clin. Microbiol 1995, 33:3225-3233. |
| [13] | Desjardin, L. E., Perkins, M., Teixeira, L., Cave, M. D., & Eisenach, K. D: Alkaline Decontamination of Sputum Specimens Adversely Affects Stability of Mycobacterial mRNA. Journal of Clinical Microbiology 1996, 34(10):2435–2439. |
| [14] | Rustad, Tige R., Minch, Kyle J., Brabant, William., Winkler, Jessica K., Reiss, David J., Baliga, Nitin S., Sherman, David R: Global analysis of mRNA stability in Mycobacterium tuberculosis. Nucleic Acids Research 2013, 41(1):509–517. |
| [15] | Jain, C: Review Article: Degradation of mRNA in Escherichia coli. IUBMB Life 2002, 54:315–321. |
| [16] | Moore, D. F., Curry, J. I., Knott, C. A., & Jonas, V: Amplification of rRNA for Assessment of Treatment response of Pulmonary Tuberculosis Patients during Antimicrobial Therapy. Journal of Clinical Microbiology 1996, 34(7):1745–1749. |
| [17] | Fenhalls G, Stevens L, Moses L, Bezuidenhout J, Betts JC, HeldenPv P: In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect Immun. 2002, 70(11):6330–8. |
| [18] | Aellen S, Que YA, Guignard B, Haenni M, Moreillon P: Detection of live and antibiotic-killed bacteria by quantitative Real-Time PCR of specific fragments of rRNA. Antimicrob Agent Chemother 2006, 50(6):1913–20. |
| [19] | L. Li, C. S. Mahan, M. Palaci, L. Horter, L. Loeffelholz, J. L Johnson, R. Dietze, S. M. Debanne, M. L. Joloba, A. Okwera, W. H. Boom, K. D. Eisenach: Sputum Mycobacterium tuberculosis mRNA as a Marker of Bacteriologic Clearance in response to antituberculosis Therapy. J. Clin. Microbiol 2010, 48(1):46–51. |
| [20] | Desjardin, L. E., Perkins, M. D., Wolski, K., Haun, S., Teixeira, L., Chen, Y: Measurement of Sputum Mycobacterium tuberculosis Messenger RNA as a surrogate for response to chemotherapy. AM J Respir. Crit. Care Med 1999, 160:203-210. |
| [21] | Garg, Sanjay K, Tiwari, R. P, Tiwari, Dileep, Singh, Rupinder, Malhotra, Dolly, Ramnani, V. K, Prasad, G.B.K.S, Chandra, Ramesh, Fraziano, M, Colizzi, V, Bisen, Prakash S: Diagnosis of tuberculosis: Available technologies, limitations, and possibilities.Journal of Clinical Laboratory Analysis 2003,17(5): 155–163. |
| [22] | Jaiswal, Suresh, Prakash, Jay and Sharma, Bhoopendra: Standard Diagnostic Procedure forTuberculosis: A Review. Research and Reviews: A Journal of Life Sciences2013,:1-10 |
| [23] | Kivihya-Ndugga Lydia, van Cleeff Maarten, Juma Ernest, Kimwomi Joseph, Githui Willie, Oskam Linda, SchuitemaAnja, van Soolingen Dick, Nganga Lucy, Kibuga Daniel, Odhiambo Joseph, Klatser Paul: Comparison of PCR with the Routine Procedure for Diagnosis of Tuberculosis in a Population with High Prevalencesof Tuberculosis and Human Immunodeficiency Virus. Journal of Clinical Microbiology 2004, 42(3): 1012–1015 |
| [24] | GholoobiAida, Masoudi-KazemabadAli, MeshkatMojtaba, MeshkatZahra: Comparison of Culture and PCR Methods for Diagnosis of Mycobacteriumtuberculosis in Different Clinical Specimens. Jundishapur J Microbiol2014, 7(2): e8939 |
| [25] | Von Gabain, A., J. G. Belasco, J. L. Schottel, A. C. Y. Chang, and S. N.Cohen: Decay of mRNA in Escherichia coli: investigation of the fate of specific segments of transcripts. Proc. Natl. Acad. Sci. USA 1983, 80:653–657. |
| [26] | Jou, N.-T., Yoshimori, R. B., Mason, G. R., Louie, J. S., &Liebling, M. R: Single-Tube, Nested, Reverse Transcriptase PCR for Detection of Viable Mycobacterium tuberculosis. Journal of Clinical Microbiology 1997,35(5):1161–1165. |
| [27] | Negi, SS. ; Anand, R; Pasha, ST; Gupta, S; Basir, SF; Khare, S; Lal, S: Diagnosis Potential of IS6110, 38KDA, 65KDA, 85B Sequence-Based Polymerase Chain Reaction in the Diagnosis of Mycobacterium tuberculosis in Clinical Samples. Indian Journal of Medical Microbiology 2007, 25(1):43-9. |
APA Style
Yadi Yasir, Ressy Dwiyanti, Muhammad Sabir, Andini Febrianty, Ahmad Adhyka, et al. (2015). Monitoring Microbiological Response to Antituberculosis Therapy by Real-Time PCR. American Journal of Clinical and Experimental Medicine, 3(1), 1-5. https://doi.org/10.11648/j.ajcem.20150301.11
ACS Style
Yadi Yasir; Ressy Dwiyanti; Muhammad Sabir; Andini Febrianty; Ahmad Adhyka, et al. Monitoring Microbiological Response to Antituberculosis Therapy by Real-Time PCR. Am. J. Clin. Exp. Med. 2015, 3(1), 1-5. doi: 10.11648/j.ajcem.20150301.11
AMA Style
Yadi Yasir, Ressy Dwiyanti, Muhammad Sabir, Andini Febrianty, Ahmad Adhyka, et al. Monitoring Microbiological Response to Antituberculosis Therapy by Real-Time PCR. Am J Clin Exp Med. 2015;3(1):1-5. doi: 10.11648/j.ajcem.20150301.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajcem.20150301.11,
author = {Yadi Yasir and Ressy Dwiyanti and Muhammad Sabir and Andini Febrianty and Ahmad Adhyka and Nur Indah Purnamasari and Muhammad Reza Primaguna and Nataniel Tandirogang and Masyhudi Amir and Syamsu Rijal and Rosdiana Natzir and SutjiPratiwi Rahardjo and Mochammad Hatta},
title = {Monitoring Microbiological Response to Antituberculosis Therapy by Real-Time PCR},
journal = {American Journal of Clinical and Experimental Medicine},
volume = {3},
number = {1},
pages = {1-5},
doi = {10.11648/j.ajcem.20150301.11},
url = {https://doi.org/10.11648/j.ajcem.20150301.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20150301.11},
abstract = {Background: M. tuberculosis grows slowly and requires several weeks to detect in clinical specimens using standard culture techniques. Messenger RNA is more rapidly destroyed in cells than rRNA or genomic DNA, assays that target mycobacterial mRNA better reflect mycobacterial viability. Therefore we evaluated performance of mRNA for monitoring response to antituberculosis therapy using Real-Time PCR. Methods: Sputum specimens from 29 tuberculosis patients confirmed by positive culture were included in this study. Sputum specimens were collected before therapy, at 1st week, 4th week, 8th week and 16th week after initiating antituberculosis therapy to evaluate acid-fast bacilli (AFB), culture and mRNA level. Results: All 29 specimens were positive for culture and mRNA before initiating tuberculosis chemotherapy. Within 29 samples confirmed by positive culture, only 22 (75.9%) patients were positive by AFB. After 8 and 16 weeks of therapy, 27 (93.1%) and 28 (96.5%) were negative by culture, 26 (89.6%) and 28 (96.5%) were negative results for mRNA, and 15 (51.7%) and 29 (100%) were negative results for AFB. Conclusion: Rapidly decline of mRNA level correlated with rapid culture clearance after anti-tuberculosis therapy.},
year = {2015}
}
TY - JOUR T1 - Monitoring Microbiological Response to Antituberculosis Therapy by Real-Time PCR AU - Yadi Yasir AU - Ressy Dwiyanti AU - Muhammad Sabir AU - Andini Febrianty AU - Ahmad Adhyka AU - Nur Indah Purnamasari AU - Muhammad Reza Primaguna AU - Nataniel Tandirogang AU - Masyhudi Amir AU - Syamsu Rijal AU - Rosdiana Natzir AU - SutjiPratiwi Rahardjo AU - Mochammad Hatta Y1 - 2015/01/19 PY - 2015 N1 - https://doi.org/10.11648/j.ajcem.20150301.11 DO - 10.11648/j.ajcem.20150301.11 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 1 EP - 5 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20150301.11 AB - Background: M. tuberculosis grows slowly and requires several weeks to detect in clinical specimens using standard culture techniques. Messenger RNA is more rapidly destroyed in cells than rRNA or genomic DNA, assays that target mycobacterial mRNA better reflect mycobacterial viability. Therefore we evaluated performance of mRNA for monitoring response to antituberculosis therapy using Real-Time PCR. Methods: Sputum specimens from 29 tuberculosis patients confirmed by positive culture were included in this study. Sputum specimens were collected before therapy, at 1st week, 4th week, 8th week and 16th week after initiating antituberculosis therapy to evaluate acid-fast bacilli (AFB), culture and mRNA level. Results: All 29 specimens were positive for culture and mRNA before initiating tuberculosis chemotherapy. Within 29 samples confirmed by positive culture, only 22 (75.9%) patients were positive by AFB. After 8 and 16 weeks of therapy, 27 (93.1%) and 28 (96.5%) were negative by culture, 26 (89.6%) and 28 (96.5%) were negative results for mRNA, and 15 (51.7%) and 29 (100%) were negative results for AFB. Conclusion: Rapidly decline of mRNA level correlated with rapid culture clearance after anti-tuberculosis therapy. VL - 3 IS - 1 ER -
Email: